Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Curran Healy, Ph.D.

Co-Author

Back to Details
This page shows the publications co-authored by Brian Healy and Bonnie Glanz.
Brian Healy
Connection Strength
11.940
Bonnie Glanz
  1. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Qual Life Res. 2021 Nov 16.
    View in: PubMed
    Score: 0.970
  2. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211007523.
    View in: PubMed
    Score: 0.937
  3. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Mult Scler. 2021 04; 27(4):593-602.
    View in: PubMed
    Score: 0.867
  4. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Mult Scler Relat Disord. 2020 May; 40:101944.
    View in: PubMed
    Score: 0.853
  5. Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. Mult Scler. 2019 11; 25(13):1791-1799.
    View in: PubMed
    Score: 0.786
  6. Risk attitudes and risk perceptions in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016 Jan-Dec; 2:2055217316665406.
    View in: PubMed
    Score: 0.676
  7. Treatment satisfaction in multiple sclerosis. Int J MS Care. 2014; 16(2):68-75.
    View in: PubMed
    Score: 0.562
  8. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012 Dec; 15(8):1029-35.
    View in: PubMed
    Score: 0.518
  9. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res. 2012 Dec; 21(10):1677-84.
    View in: PubMed
    Score: 0.490
  10. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):2055217321999070.
    View in: PubMed
    Score: 0.233
  11. Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. J Psychosom Res. 2020 11; 138:110252.
    View in: PubMed
    Score: 0.224
  12. An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial. Int J MS Care. 2021 May-Jun; 23(3):128-134.
    View in: PubMed
    Score: 0.223
  13. A Pilot Study to Assess At-Home Speed of Processing Training for Individuals with Multiple Sclerosis. Mult Scler Int. 2019; 2019:3584259.
    View in: PubMed
    Score: 0.205
  14. Computerized Cognitive Behavioral Therapy for Treatment of Depression in Multiple Sclerosis: A Narrative Review of Current Findings and Future Directions. Int J MS Care. 2019 May-Jun; 21(3):113-123.
    View in: PubMed
    Score: 0.203
  15. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019 Feb 12; 19(1):23.
    View in: PubMed
    Score: 0.200
  16. Time between expanded disability status scale (EDSS) scores. Mult Scler Relat Disord. 2019 May; 30:98-103.
    View in: PubMed
    Score: 0.200
  17. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. J Neurol Sci. 2018 11 15; 394:127-131.
    View in: PubMed
    Score: 0.195
  18. Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. Int J MS Care. 2018 May-Jun; 20(3):136-141.
    View in: PubMed
    Score: 0.190
  19. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017 Nov; 18:196-201.
    View in: PubMed
    Score: 0.182
  20. Depression and fatigue in patients with multiple sclerosis. J Neurol Sci. 2017 Sep 15; 380:236-241.
    View in: PubMed
    Score: 0.180
  21. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.175
  22. Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. Mult Scler Relat Disord. 2015 Nov; 4(6):598-606.
    View in: PubMed
    Score: 0.158
  23. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int. 2013; 2013:189624.
    View in: PubMed
    Score: 0.133
  24. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan; 83(1):38-43.
    View in: PubMed
    Score: 0.118
  25. Patient reported outcomes in benign multiple sclerosis. Mult Scler. 2011 Jul; 17(7):876-84.
    View in: PubMed
    Score: 0.115
  26. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010 Dec; 16(12):1483-9.
    View in: PubMed
    Score: 0.111
  27. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.111
  28. The association between cognitive impairment and quality of life in patients with early multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):75-9.
    View in: PubMed
    Score: 0.106
  29. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.103
  30. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009 May; 15(5):627-31.
    View in: PubMed
    Score: 0.101
  31. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069348.
    View in: PubMed
    Score: 0.061
  32. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211015503.
    View in: PubMed
    Score: 0.059
  33. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 06; 89(6):1195-1211.
    View in: PubMed
    Score: 0.058
  34. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2021 03; 8(3):631-638.
    View in: PubMed
    Score: 0.057
  35. Identification of a predominant cognitive phenotype in patients with multiple sclerosis. Eur J Neurol. 2020 06; 27(6):1083-1088.
    View in: PubMed
    Score: 0.054
  36. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019 Dec 11; 2(1):123.
    View in: PubMed
    Score: 0.053
  37. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019; 2:123.
    View in: PubMed
    Score: 0.053
  38. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 10 14; 9(1):14781.
    View in: PubMed
    Score: 0.052
  39. Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Mult Scler. 2020 11; 26(13):1708-1718.
    View in: PubMed
    Score: 0.052
  40. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
    View in: PubMed
    Score: 0.052
  41. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019 Aug 15; 403:38-43.
    View in: PubMed
    Score: 0.051
  42. Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Mult Scler J Exp Transl Clin. 2019 Jan-Mar; 5(1):2055217319828400.
    View in: PubMed
    Score: 0.050
  43. Food allergies are associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019 06; 90(6):629-635.
    View in: PubMed
    Score: 0.050
  44. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1478-1491.
    View in: PubMed
    Score: 0.049
  45. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
    View in: PubMed
    Score: 0.048
  46. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. 2018 06; 83(6):1147-1161.
    View in: PubMed
    Score: 0.048
  47. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Aug; 58(2):261-269.
    View in: PubMed
    Score: 0.047
  48. Investigation of probiotics in multiple sclerosis. Mult Scler. 2018 01; 24(1):58-63.
    View in: PubMed
    Score: 0.046
  49. Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. J Neuroimaging. 2018 05; 28(3):273-277.
    View in: PubMed
    Score: 0.046
  50. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Mult Scler Relat Disord. 2017 Oct; 17:47-53.
    View in: PubMed
    Score: 0.045
  51. Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. Mult Scler. 2018 07; 24(8):1126-1130.
    View in: PubMed
    Score: 0.045
  52. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e267.
    View in: PubMed
    Score: 0.042
  53. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Front Neurol. 2016; 7:99.
    View in: PubMed
    Score: 0.042
  54. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Mult Scler. 2016 12; 22(14):1841-1849.
    View in: PubMed
    Score: 0.041
  55. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167.
    View in: PubMed
    Score: 0.040
  56. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016 06; 22(7):935-43.
    View in: PubMed
    Score: 0.040
  57. The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. Neurology. 2015 Oct 06; 85(14):1209-13.
    View in: PubMed
    Score: 0.039
  58. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Nov; 262(11):2425-32.
    View in: PubMed
    Score: 0.039
  59. Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. J Neuroimaging. 2016 Jan-Feb; 26(1):62-7.
    View in: PubMed
    Score: 0.039
  60. Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Mult Scler. 2016 Mar; 22(3):354-61.
    View in: PubMed
    Score: 0.039
  61. Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors. J Neuroimaging. 2015 Mar-Apr; 25(2):191-199.
    View in: PubMed
    Score: 0.038
  62. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.037
  63. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014 Oct; 20(12):1584-92.
    View in: PubMed
    Score: 0.036
  64. Improving the quality of mental health care in multiple sclerosis. J Neurol Sci. 2013 Dec 15; 335(1-2):42-7.
    View in: PubMed
    Score: 0.034
  65. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 03; 13:73.
    View in: PubMed
    Score: 0.034
  66. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One. 2013; 8(3):e59707.
    View in: PubMed
    Score: 0.033
  67. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.031
  68. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.029
  69. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. AJNR Am J Neuroradiol. 2011 Mar; 32(3):515-21.
    View in: PubMed
    Score: 0.029
  70. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr; 12(3):183-90.
    View in: PubMed
    Score: 0.028
  71. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.025
  72. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.